Renal tumors antigens

Unwin, R. D., Hamden, P., Pappin, D., Rahman, D., Whelan, P., Craven, R. A., et al. (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3,45-55. 

Ahorn, H., Zatloukal, K., Pummee, K., Addle, G. R. (2001). Identification of tumor antigens in renal call carcinoma by serological proteome analysis. Proteomics 1, 890-898. 

Bakshi N, Kunju LP, Giordano T, Shah RB. Expression of renal carcinoma antigen in renal epithelial and non-renal tumors Diagnostic implications. Appl Immunohistochem Mol Morphol. 2007 15 310-315. 

Kellner, R., Lichteneels, R., Atkins, D., Bukur,J., Ackermann, a.. Beck, J., Brenner, W., Melchior, S., Seliger, B. (2002). Targeting of tumor-associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2, 1743-1751. 

Antitumor responses have been observed with NMT in patients with renal cell carcinoma, melanoma, breast cancer, and other solid tumors. In order to improve on the efficacy seen with NMT, some investigators are evaluating novel approaches to enhance allogeneic immune responses against tumor-associated antigens (if available) such as posttransplant vaccination. 

Cote RJ, Cardon-Cardo C, Reuter VE, Rosen PP. Immuno-pathology of adrenal and renal cortical tumors Coordinated change in antigen expression is associated with neoplastic conversion in the adrenal cortex. Am J Pathol. 1990 136 1077-1084. 

D2-40, a clone of podoplanin, is a recently developed commercially available antibody directed against the M2A antigen, a 40,000-kD sialoglycoprotein associated with germ cells and lymphatic endothelium. Chu and colleagues evaluated 53 cases of mesothelioma, 28 cases of reactive pleural tissue, 30 cases of pulmonary adenocarcinoma, 35 cases of renal cell carcinoma, 26 cases of ovarian serous carcinoma, 16 cases of invasive breast carcinoma, 11 cases of prostatic adenocarcinoma, and 7 cases of urothelial carcinoma. The authors found D2-40 expression in 51 of 53 (96%) mesotheliomas, 27 of 28 (96%) reactive pleural tissues, and 17 of 26 (65%) ovarian serous carcinomas. They did not find D2-40 in the other tumors examined. The authors also observed that the neoplastic cells immunostained in a cell membrane distribution. 

TroVax immunotherapy for renal cell carcinoma consists of the gene for the 5T4 tumor-associated antigen, which is delivered to the body by means of a viral vector. This vaccine is currently undergoing phase III trials. 

---